Cargando…
Breastfeeding patterns and its determinants among mothers living with Human Immuno-deficiency Virus -1 in four African countries participating in the ANRS 12174 trial
BACKGROUND: HIV-1 transmission rates have been reduced over the last decade, an estimated 2 million new infections per year arise, including 220,000 paediatric cases. The main post-natal HIV exposure is through breastfeeding, where both its duration and modality (exclusive or not) are associated wit...
Autores principales: | Somé, Eric N., Engebretsen, Ingunn M. S., Nagot, Nicolas, Meda, Nicolas, Lombard, Carl, Vallo, Roselyne, Peries, Marianne, Kankasa, Chipepo, Tumwine, James K., Hofmeyr, G. Justus, Singata, Mandisa, Harper, Kim, Van De Perre, Philippe, Tylleskar, Thorkild |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5414228/ https://www.ncbi.nlm.nih.gov/pubmed/28469697 http://dx.doi.org/10.1186/s13006-017-0112-2 |
Ejemplares similares
-
Changes in body mass index and hemoglobin concentration in breastfeeding women living with HIV with a CD4 count over 350: Results from 4 African countries (The ANRS 12174 trial)
por: Somé, Eric Nagaonlé, et al.
Publicado: (2017) -
HIV-1 disease progression in immune-competent HIV-1-infected and breastfeeding mothers participating in the ANRS 12174 clinical trial in Burkina Faso, South Africa, Uganda and Zambia: a cohort study
por: Somé, Eric Nagaonle, et al.
Publicado: (2018) -
Lopinavir/Ritonavir versus Lamivudine peri-exposure prophylaxis to prevent HIV-1 transmission by breastfeeding: the PROMISE-PEP trial Protocol ANRS 12174
por: Nagot, Nicolas, et al.
Publicado: (2012) -
Mitochondrial DNA Parameters in Blood of Infants Receiving Lopinavir/Ritonavir or Lamivudine Prophylaxis to Prevent Breastfeeding Transmission of HIV-1
por: Monnin, Audrey, et al.
Publicado: (2020) -
Growth, clinical and neurodevelopmental outcomes at school age are similar for children who received 1-year lamivudine or lopinavir/ritonavir HIV prophylaxis in early life
por: Nagot, Nicolas, et al.
Publicado: (2021)